Rankings
▼
Calendar
MDGL Q3 2016 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
MDGL
Madrigal Pharmaceuticals, Inc.
$10B
Q3 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$14M
Net Income
-$14M
EPS (Diluted)
$-1.59
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
$7M
Free Cash Flow
$7M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$42M
Total Liabilities
$4M
Stockholders' Equity
$38M
Cash & Equivalents
$8M
← FY 2016
All Quarters
Q4 2016 →
